Catalyst Biosciences Valuation
| CBIODelisted Stock | USD 0.41 0.02 4.65% |
Catalyst Biosciences is overvalued. Catalyst Biosciences shows a prevailing Real Value of $0.31 per share. The current price of the firm is $0.41. Our model approximates the value of Catalyst Biosciences from analyzing the firm fundamentals such as Return On Equity of -2.69, shares owned by insiders of 27.73 %, and Current Valuation of 51.03 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Catalyst Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Catalyst Biosciences is based on 3 months time horizon. Increasing Catalyst Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Catalyst Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Catalyst Stock. However, Catalyst Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.41 | Real 0.31 | Hype 0.41 |
The intrinsic value of Catalyst Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Catalyst Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Catalyst Biosciences helps investors to forecast how Catalyst stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Catalyst Biosciences more accurately as focusing exclusively on Catalyst Biosciences' fundamentals will not take into account other important factors: Catalyst Biosciences Total Value Analysis
Catalyst Biosciences is currently forecasted to have valuation of 51.03 M with market capitalization of 19.37 M, debt of 38 K, and cash on hands of 75.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Catalyst Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
51.03 M | 19.37 M | 38 K | 75.39 M |
Catalyst Biosciences Investor Information
About 28.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.53. Some equities with similar Price to Book (P/B) outperform the market in the long run. Catalyst Biosciences has Price/Earnings To Growth (PEG) ratio of 0.02. The entity recorded a loss per share of 1.5. The firm last dividend was issued on the 13th of January 2023. Catalyst Biosciences had 1:15 split on the 13th of February 2017. Based on the key indicators related to Catalyst Biosciences' liquidity, profitability, solvency, and operating efficiency, Catalyst Biosciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Catalyst Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Catalyst Biosciences has an asset utilization ratio of 2.79 percent. This suggests that the Company is making $0.0279 for each dollar of assets. An increasing asset utilization means that Catalyst Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Catalyst Biosciences Ownership Allocation
Catalyst Biosciences holds a total of 37.97 Million outstanding shares. Catalyst Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Catalyst Biosciences Profitability Analysis
The company reported the previous year's revenue of 794 K. Net Loss for the year was (8.24 M) with loss before overhead, payroll, taxes, and interest of (64.91 M).Catalyst Biosciences Past Distributions to stockholders
About Catalyst Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Catalyst Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Catalyst Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Catalyst Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Catalyst Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Catalyst Biosciences. We calculate exposure to Catalyst Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Catalyst Biosciences's related companies.Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California. Catalyst Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
A single share of Catalyst Biosciences represents a small ownership stake in the entity. As a stockholder of Catalyst, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Catalyst Biosciences Dividends Analysis For Valuation
Please note that Catalyst Biosciences has scaled down on payment of dividends at this time.
There are various types of dividends Catalyst Biosciences can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Catalyst shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Catalyst Biosciences directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Catalyst pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Catalyst Biosciences by the value of the dividends paid out.
Catalyst Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 31.5 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |